FOLF(HA)iri: Trial of FOLF(HA)Iri Versus FOLFIRI in mCRC
Study Details
Study Description
Brief Summary
Trial design:
-
Phase III, FOLFIRI versus FOLF(HA)iri (the FOLFIRI regimen with "Hyaluronic acid-Irinotecan" or "HA-Irinotecan") regimen.
-
Patients with mCRC (metastatic colorectal cancer), 2nd/3rd line irinotecan naïve.
-
Randomized 1:1, double-blinded, multi-centre, multi-national (Australia, Bulgaria, Poland, Serbia, Russia, Ukraine and the United Kingdom).
-
Dosing regimen:
-
Irinotecan (180 mg/m2) or HA-Irinotecan (180 mg/m2), IV, over 90 minutes, day 1 (in patients > 75 years of age, the irinotecan and HA-Irinotecan dose in must be reduced to 150 mg/m2).
-
Leucovorin, 400 mg/m2, or levoleucovorin, 200 mg/m2, IV over 90 minutes with irinotecan.
-
5-fluorouracil (5-FU), 400 mg/m2 IV bolus day 1, then 1200 mg/m2/day x 2 days (total 2400 mg/m2 over 46-48 hours) continuous infusion.
-
Repeat every 2 weeks for 8 months.
-
Patient accrual over approximately 12-14 months.
-
Monitoring to 18 months post-randomization.
-
390 patients.
-
Progression Free Survival (PFS) primary endpoint.
-
Safety analysis on the initial 20 patients.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
Phase 3 |
Study Design
Arms and Interventions
Arm | Intervention/Treatment |
---|---|
Active Comparator: FOLFIRI
|
Drug: Irintoecan
Irinotecan, 180 mg/m2 IV, over 90 minutes, day 1 (in patients > 75 years of age, the irinotecan dose in must be reduced to 150 mg/m2).
Leucovorin, 400 mg/m2, or levoleucovorin, 200 mg/m2, IV over 90 minutes with irinotecan.
5-FU, 400 mg/m2 IV bolus day 1, then 1200 mg/m2/day x 2 days (total 2400 mg/m2 over 46-48 hours) continuous infusion.
Repeat every two weeks.
8 months of treatment.
|
Experimental: FOLF(HA)iri
|
Drug: HA-Irinotecan solution for Infusion
HA-Irinotecan (irinotecan 180 mg/m2), IV, over 90 minutes, day 1 (in patients > 75 years of age, the irinotecan dose in must be reduced to 150 mg/m2).
Leucovorin, 400 mg/m2, or levoleucovorin, 200 mg/m2, IV over 90 minutes with irinotecan.
5-FU, 400 mg/m2 IV bolus day 1, then 1200 mg/m2/day x 2 days (total 2400 mg/m2 over 46-48 hours) continuous infusion.
Repeat every two weeks
8 months of treatment.
|
Outcome Measures
Primary Outcome Measures
- Progression Free Survival (PFS) [Approximately 20 months]
Secondary Outcome Measures
- Safety [After initial 20 patients receive 2 cycles, then 6 monthly thereafter.]
Diarrhea and haematology
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Metastatic colorectal cancer with disease progression after first or second line chemotherapy
-
Irinotecan naïve.
-
ECOG performance status of 0 or 1.
-
Measurable disease, i.e. at least one measurable metastatic lesion (spiral CT or MRI).
-
Histological proof of colorectal cancer.
-
18 years of age and older.
-
Adequately recovered from and at least 4 weeks after recent surgery or chemotherapy.
-
Women of child-bearing potential (WOCBP) and male partners of WOCBP must agree to use adequate contraception.
-
Patient consent obtained and signed according to local and/or national ethics.
-
CT or MRI scan of chest/abdomen/pelvis within 21 days prior to randomization.
-
Hematology done within 14 days prior to randomization.
-
Chemistry done within 14 days prior to randomization.
Exclusion Criteria:
-
History of other malignancies, except adequately treated non-melanoma skin cancer, curatively treated in-situ cancer of the cervix, or other solid tumors curatively treated with no evidence of disease for > 5 years.
-
Locally advanced or recurrent disease only.
-
Unsuitability for irinotecan including known Gilbert's syndrome, active inflammatory bowel disease or chronic diarrhea greater than or equal to grade 2.
-
Abdominal or pelvic radiation therapy within the last 12 months.
-
Women who are pregnant or breastfeeding.
-
Any condition (e.g., psychological, geographical) that would render the protocol treatment dangerous.
-
Significant cardiac disease.
-
Untreated or symptomatic brain or central nervous system (CNS).
-
Presence of pleural effusion or ascites requiring therapeutic thoracocentesis or paracentesis.
-
Current partial or complete bowel obstruction.
-
Concomitant active infection.
-
Enrolled in any other investigational trial, unless treatment in that trial has been discontinued at least 30 days prior to signing the Informed Consent for the ACO-002 study.
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | Southern Medical Day Care Centre | Wollongong | New South Wales | Australia | 2500 |
2 | Western General Hospital | Melbourne | Victoria | Australia | 3011 |
3 | Royal Melbourne Hospital | Melbourne | Victoria | Australia | 3050 |
4 | Monash Medical Centre | Melbourne | Victoria | Australia | 3165 |
5 | Border Medical Oncology | Wodonga | Victoria | Australia | 3690 |
Sponsors and Collaborators
- Alchemia Oncology
Investigators
- Principal Investigator: Peter Gibbs, MD, Melbourne Health
Study Documents (Full-Text)
None provided.More Information
Publications
- ACO-002